1. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance;Moore;Lancet Infect Dis,2015
2. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults;Bonten;N Engl J Med,2015
3. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States;Stoecker;J Gen Intern Med,2016
4. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP);Tomczyk;MMWR Morb Mortal Wkly Rep,2014
5. Matanock A. Considerations for PCV13 use among adults >65 years old and a summary of the evidence to recommendations framework. Advisory Committee on Immunization Practices, June 2019 Meeting.www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-06/Pneumococcal-2-Matanock-508.pdf. Updated August 29, 2019. Accessed November 5, 2019.